{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:31Z","timestamp":1791407371126,"version":"4.3.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12916-015-0297-4","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T11:42:54Z","timestamp":1427283774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Advances in Alzheimer\u2019s Disease Drug Development"],"prefix":"10.1186","volume":"13","author":[{"given":"Michael S","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,25]]},"reference":[{"key":"297_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2012.11.006","volume":"9","author":"A Wimo","year":"2013","unstructured":"Wimo A, Jonsson L, Bond J, Prince M, Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9:1\u201311. e3.","journal-title":"Alzheimers Dement"},{"key":"297_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology."},{"key":"297_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol."},{"key":"297_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1006\/exnr.2000.7397","volume":"163","author":"RT Bartus","year":"2000","unstructured":"Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495\u2013529.","journal-title":"Exp Neurol."},{"key":"297_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT, Dean 3rd RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408\u201314.","journal-title":"Science."},{"key":"297_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"8000","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet. 1976;8000:1403.","journal-title":"Lancet."},{"key":"297_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/0091-3057(78)90364-7","volume":"9","author":"RT Bartus","year":"1978","unstructured":"Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav. 1978;9:833\u20136.","journal-title":"Pharmacol Biochem Behav."},{"key":"297_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000051272","volume":"12","author":"RS Doody","year":"2001","unstructured":"Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2001;12:295\u2013300.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"297_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd3822","volume":"11","author":"S Ness","year":"2012","unstructured":"Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down\u2019s syndrome and Alzheimer\u2019s disease: towards secondary prevention. Nat Rev Drug Discov. 2012;11:655\u20136.","journal-title":"Nat Rev Drug Discov."},{"key":"297_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488:96\u20139.","journal-title":"Nature."},{"key":"297_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neurobiolaging.2005.01.011","volume":"27","author":"RB Maccioni","year":"2006","unstructured":"Maccioni RB, Lavados M, Maccioni CB, Mujica C, Bosch R, Far\u00edas G, et al. Anomalously phosphorylated tau protein and Abeta fragments in the CSF of Alzheimer\u2019s and MCI subjects. Neurobiol Aging. 2006;27:237\u201344.","journal-title":"Neurobiol Aging."},{"key":"297_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11910-014-0500-6","volume":"14","author":"N Okamura","year":"2014","unstructured":"Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer\u2019s disease. Curr Neurol Neurosci Rep. 2014;14:500.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"297_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJMp1302513","volume":"368","author":"N Kozauer","year":"2013","unstructured":"Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer\u2019s disease. N Engl J Med. 2013;368:1169\u201371.","journal-title":"N Engl J Med."},{"key":"297_CR14","doi-asserted-by":"crossref","unstructured":"Selkoe DJ. Alzheimer\u2019s disease. Cold Spring Harb Perspect Biol. 2011;3. doi:10.1101\/cshperspect.a004457.","DOI":"10.1101\/cshperspect.a004457"},{"key":"297_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci. 2007;8:663\u201372.","journal-title":"Nat Rev Neurosci."},{"key":"297_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-013-1139-0","volume":"126","author":"H Braak","year":"2013","unstructured":"Braak H, Zetterberg H, Del Tredici K, Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-\u03b2 changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013;126:631\u201341.","journal-title":"Acta Neuropathol."},{"key":"297_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-7091-6467-9_15","volume":"53","author":"K Iqbal","year":"1998","unstructured":"Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, et al. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neural Transm. 1998;53:169\u201380.","journal-title":"J Neural Transm."},{"key":"297_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275\u201383.","journal-title":"Neurobiol Aging."},{"key":"297_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement."},{"key":"297_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ana.22628","volume":"71","author":"CR Jack Jr","year":"2012","unstructured":"Jack Jr CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer\u2019s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765\u201375.","journal-title":"Ann Neurol."},{"key":"297_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173\u20137.","journal-title":"Nature."},{"key":"297_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Alzheimer\u2019s Disease Cooperative Study Steering Committee; Solanezumab study group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"297_CR23","doi-asserted-by":"publisher","first-page":"P275","DOI":"10.1016\/j.jalz.2014.04.450","volume":"10","author":"J Cummings","year":"2014","unstructured":"Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer\u2019s disease. Alzheimers Demen. 2014;10:P275.","journal-title":"Alzheimers Demen"},{"key":"297_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-beta-amyloid antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J Alzheimers Dis. 2012;28:49\u201369.","journal-title":"J Alzheimers Dis."},{"key":"297_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101\u201312.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"297_CR26","volume-title":"64th American Academy of Neurology Annual Meeting","author":"M Forman","year":"2012","unstructured":"Forman M, Tseng J, Palcza J, Leempoels J, Ramael S, Krishna G. The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid peptides in healthy subjects: results from a rising single dose study (PL02. 004). In: 64th American Academy of Neurology Annual Meeting. New Orleans: Neurology; 2012."},{"key":"297_CR27","doi-asserted-by":"crossref","unstructured":"Forman MS PJ, Tseng J, Dockendorf M, Canales C, Apter J, Backonja M, et al. The novel BACe inhibitor MK-8931 dramatically lowers CSF Abeta peptide in patients with mild to moderate Alzheimer\u2019s disease. In: The 11th International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease. Florence, Italy. 2013.","DOI":"10.1016\/j.jalz.2013.04.083"},{"key":"297_CR28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/JAD-2009-1118","volume":"8","author":"JM Ryan","year":"2009","unstructured":"Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer\u2019s disease: ACC-001 clinical trials are ongoing. J Alzheimer Dis. 2009;8:243.","journal-title":"J Alzheimer Dis."},{"key":"297_CR29","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1073\/pnas.0703137104","volume":"8","author":"A Muhs","year":"2007","unstructured":"Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens N, Meerschman C, et al. Liposomal vaccines with conformation-specific amyloid antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A. 2007;8:9810\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"297_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","volume":"8","author":"B Winblad","year":"2012","unstructured":"Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active beta-amyloid immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;8:597\u2013604.","journal-title":"Lancet Neurol."},{"key":"297_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","volume":"6","author":"CA Lemere","year":"2010","unstructured":"Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108\u201319.","journal-title":"Nat Rev Neurol."},{"key":"297_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med."},{"key":"297_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2174\/156720509789207930","volume":"6","author":"EM Sigurdsson","year":"2009","unstructured":"Sigurdsson EM. Tau-focused immunotherapy for Alzheimer\u2019s disease and related tauopathies. Curr Alzheimer Res. 2009;6:446\u201350.","journal-title":"Curr Alzheimer Res."},{"key":"297_CR34","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"AA Asuni","year":"2007","unstructured":"Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115\u201329.","journal-title":"J Neurosci."},{"key":"297_CR35","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1523\/JNEUROSCI.06-08-02155.1986","volume":"6","author":"F Hefti","year":"1986","unstructured":"Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci. 1986;6:2155\u201362.","journal-title":"J Neurosci."},{"key":"297_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","volume":"10","author":"MS Rafii","year":"2014","unstructured":"Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:571\u201381.","journal-title":"Alzheimers Dement."},{"key":"297_CR37","first-page":"672","volume":"10","author":"AM Schmidt","year":"2009","unstructured":"Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer\u2019s disease. Curr Opin Investig Drugs. 2009;10:672\u201380.","journal-title":"Curr Opin Investig Drugs."},{"key":"297_CR38","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","volume":"82","author":"D Galasko","year":"2014","unstructured":"Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, et al. Clinical trial of an inhibitor of RAGE-beta-amyloid interactions in Alzheimer disease. Neurology. 2014;82:1536\u201342.","journal-title":"Neurology."},{"key":"297_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-14-12","volume":"14","author":"AH Burstein","year":"2014","unstructured":"Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer\u2019s disease. BMC Neurol. 2014;14:12.","journal-title":"BMC Neurol."},{"key":"297_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","volume":"62","author":"J Prickaerts","year":"2012","unstructured":"Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, et al. EVP-6124, a novel and selective \u03b17 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of \u03b17 nicotinic acetylcholine receptors. Neuropharmacology. 2012;62:1099\u2013110.","journal-title":"Neuropharmacology."},{"key":"297_CR41","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1345\/aph.1Q238","volume":"45","author":"BW Miller","year":"2011","unstructured":"Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer\u2019s disease. Ann Pharmacother. 2011;45:1416\u201324.","journal-title":"Ann Pharmacother."},{"key":"297_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00001756-199304000-00024","volume":"4","author":"SK Shirazi","year":"1993","unstructured":"Shirazi SK, Wood JG. The protein tyrosine kinase, Fyn, in Alzheimer\u2019s disease pathology. Neuroreport. 1993;4:435\u20137.","journal-title":"Neuroreport."},{"key":"297_CR43","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1523\/JNEUROSCI.0277-04.2004","volume":"24","author":"J Chin","year":"2004","unstructured":"Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692\u20137.","journal-title":"J Neurosci."},{"key":"297_CR44","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1523\/JNEUROSCI.4162-03.2004","volume":"24","author":"G Lee","year":"2004","unstructured":"Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, et al. Phosphorylation of tau by Fyn: implications for Alzheimer\u2019s disease. J Neurosci. 2004;24:2304\u201312.","journal-title":"J Neurosci."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-015-0297-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0297-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T11:19:12Z","timestamp":1566472752000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-015-0297-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1186\/s12916-015-0297-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,25]]},"article-number":"62"}}